Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report)’s share price traded up 8.4% on Wednesday . The stock traded as high as $0.6827 and last traded at $0.6650. 78,493 shares were traded during trading, an increase of 186% from the average session volume of 27,399 shares. The stock had previously closed at $0.6133.
Defence Therapeutics Price Performance
The stock has a fifty day moving average price of $0.55 and a two-hundred day moving average price of $0.55.
Defence Therapeutics Company Profile
Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.
Featured Articles
- Five stocks we like better than Defence Therapeutics
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- 3 Stocks Poised to Benefit From Google’s AI Breakthough
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026
- Why Invest in 5G? How to Invest in 5G Stocks
- 3 Stocks You’ll Wish You Bought Before 2026
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
